Omapatrilat provides long-term control of hypertension: a randomized trial of treatment withdrawal
{{output}}
Omapatrilat simultaneously inhibits neutral endopeptidase and angiotensin-converting enzyme, increasing levels of vasodilatory peptides while decreasing production of angiotensin II. This study evaluated the clinical effects of withdrawal of omapatrilat after ... ...
